Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HSAQNASDAQ:ICADNYSE:INFUNASDAQ:LUCD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSAQHealth Sciences Acquisitions Co. 2$2.94+10.9%$3.28$9.41▼$13.80$32.96M0.09205,918 shs263,163 shsICADiCAD$3.91-0.5%$2.58$1.18▼$4.00$107.31M1.35402,565 shs409,846 shsINFUInfuSystem$5.73-0.3%$5.26$4.61▼$9.97$120.42M1.7391,413 shs156,480 shsLUCDLucid Diagnostics$1.28+7.6%$1.36$0.68▼$1.80$134.89M1.28494,952 shs1.54 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSAQHealth Sciences Acquisitions Co. 20.00%+3.52%-11.07%-50.74%-42.39%ICADiCAD+5.93%+12.45%+120.79%+11.33%+151.92%INFUInfuSystem+4.93%+22.34%+15.46%-28.39%-23.44%LUCDLucid Diagnostics+8.18%-3.25%+1.71%-10.53%+25.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AN/AN/AN/AICADiCAD0.5348 of 5 stars0.03.00.00.03.30.80.0INFUInfuSystem1.8542 of 5 stars2.00.00.00.02.62.51.9LUCDLucid Diagnostics3.0419 of 5 stars3.65.00.00.02.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSAQHealth Sciences Acquisitions Co. 2 0.00N/AN/AN/AICADiCAD 2.00HoldN/AN/AINFUInfuSystem 4.00Strong Buy$13.00126.88% UpsideLUCDLucid Diagnostics 3.20Buy$3.50173.44% UpsideCurrent Analyst Ratings BreakdownLatest HSAQ, LUCD, INFU, and ICAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/17/2025ICADiCADLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/16/2025ICADiCADBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/16/2025ICADiCADCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/11/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/26/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.003/25/2025LUCDLucid DiagnosticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.003/24/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.50 ➝ $3.003/18/2025INFUInfuSystemSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/A($0.62) per shareN/AICADiCAD$19.61M5.47N/AN/A$1.27 per share3.08INFUInfuSystem$137.58M0.88$0.45 per share12.79$2.47 per share2.32LUCDLucid Diagnostics$4.35M31.04N/AN/A($0.47) per share-2.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSAQHealth Sciences Acquisitions Co. 2-$380KN/A0.00∞N/AN/AN/A-2.38%N/AICADiCAD-$4.85M-$0.21N/A∞N/A-17.81%-15.65%-12.52%N/AINFUInfuSystem$870K$0.1495.5218.48N/A1.12%2.78%1.41%N/ALUCDLucid Diagnostics-$52.67M-$1.08N/AN/AN/A-1,069.87%N/A-123.54%5/14/2025 (Estimated)Latest HSAQ, LUCD, INFU, and ICAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025LUCDLucid Diagnostics-$0.13-$0.17-$0.04-$0.66$1.30 millionN/A5/13/2025Q1 2025ICADiCAD-$0.0625-$0.02+$0.0425-$0.03$4.54 million$4.87 million3/19/2025Q4 2024ICADiCAD-$0.0525-$0.03+$0.0225-$0.03$4.72 million$5.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AICADiCADN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSAQHealth Sciences Acquisitions Co. 2N/A0.170.61ICADiCADN/A4.023.91INFUInfuSystem0.501.981.59LUCDLucid DiagnosticsN/A1.181.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSAQHealth Sciences Acquisitions Co. 289.71%ICADiCAD24.61%INFUInfuSystem71.13%LUCDLucid Diagnostics74.01%Insider OwnershipCompanyInsider OwnershipHSAQHealth Sciences Acquisitions Co. 221.90%ICADiCAD10.29%INFUInfuSystem10.20%LUCDLucid Diagnostics8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSAQHealth Sciences Acquisitions Co. 2411.21 million8.76 millionNot OptionableICADiCAD14027.45 million23.81 millionOptionableINFUInfuSystem41021.02 million19.10 millionOptionableLUCDLucid Diagnostics70105.38 million54.12 millionNo DataHSAQ, LUCD, INFU, and ICAD HeadlinesRecent News About These CompaniesLucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call TranscriptMay 14 at 2:14 PM | seekingalpha.comLucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue EstimatesMay 14 at 10:16 AM | zacks.comLucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14 at 8:01 AM | prnewswire.comLucid Diagnostics (LUCD) Projected to Post Quarterly Earnings on WednesdayMay 13 at 1:17 AM | americanbankingnews.comLucid Diagnostics (LUCD) to Release Earnings on WednesdayMay 9, 2025 | marketbeat.comWill Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should KnowMay 7, 2025 | zacks.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025April 30, 2025 | prnewswire.comLucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in studyApril 26, 2025 | markets.businessinsider.comLucid Diagnostics Reports Positive Data for EsoGuard in Study of Asymptomatic PatientsApril 24, 2025 | theglobeandmail.comLucid reports encouraging results from EsoGuard studyApril 24, 2025 | msn.comNCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERDApril 24, 2025 | prnewswire.comAscendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock PriceApril 23, 2025 | marketbeat.comLucid Diagnostics price target raised to $7.50 from $7 at AscendiantApril 22, 2025 | markets.businessinsider.comLucid Diagnostics Closes $16.1 Million Public OfferingApril 11, 2025 | tipranks.comLucid Diagnostics Announces Closing of Public Offering of Common StockApril 11, 2025 | prnewswire.comLucid Diagnostics 12.5M share Spot Secondary priced at $1.20April 10, 2025 | markets.businessinsider.comLucid Diagnostics announces common stock offering, no amount givenApril 10, 2025 | markets.businessinsider.comLucid Diagnostics stock falls after pricing capital raise of $15M via stock offeringApril 10, 2025 | msn.comLucid Diagnostics Stock Sinks After-Hours On Equity Raise, But Retail Dives In AnywayApril 10, 2025 | msn.comLucid Diagnostics Announces Pricing of Public Offering of Common StockApril 9, 2025 | prnewswire.comLucid Diagnostics Announces Pricing of Public Offering of Common StockApril 9, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSAQ, LUCD, INFU, and ICAD Company DescriptionsHealth Sciences Acquisitions Co. 2 NASDAQ:HSAQ$2.94 +0.29 (+10.94%) As of 05/13/2025Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.iCAD NASDAQ:ICAD$3.91 -0.02 (-0.51%) As of 04:00 PM EasterniCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.InfuSystem NYSE:INFU$5.73 -0.02 (-0.35%) As of 04:00 PM EasternInfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Lucid Diagnostics NASDAQ:LUCD$1.28 +0.09 (+7.56%) As of 04:00 PM EasternLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
